Thermo Fisher Scientific’s TurboFlow Technology Reduces Matrix Effects in LC-MS/MS Analysis

Thermo Fisher Scientific Inc. has announced that the company’s TurboFlow™ technology can assist pharmaceutical researchers to comply with U.S. Food and Drug Administration (FDA) regulatory guidelines on matrix effects, particularly for LC-MS/MS analysis.

Thermo Scientific TurboFlow technology coupled with the Thermo Scientific TSQ Quantum™ triple quadrupole mass spectrometer and FAIMS (High-Field Asymmetric Ion Mobility Mass Spectrometry) technology provides an integrated LC-MS/MS solution.

When used with the TSQ Quantum, the system delivers quantitative results with the lowest ion suppression and chemical noise, resulting in sensitive bioanalytical methods, development of robust methods and reduction in analysis failures.

This solution can allow scientists to matrix effects during pre-clinical bioanalysis, making it easier to comply with the FDA/CDER Bioanalytical Method Validation Guidance that states: "In the case of LC-MS-MS-based procedures, appropriate steps should be taken to ensure the lack of matrix effects throughout the application of the method, especially if the nature of the matrix changes from the matrix used during method validation."

TurboFlow technology assists pharmaceutical researchers in reducing matrix effects by retaining small molecules, excluding proteins and larger materials. This enables users to directly inject biological samples into the LC-MS/MS system prior to analysis, an advantage in preclinical bioanalysis.